Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

tislelizumab-jsgr (Tevimbra)

tislelizumab-jsgr is an FDA-licensed reference biologic from BeOne Medicines USA, Inc..

351(a) biologicBLA 761232 BeOne Medicines USA, Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2026

Reference product

Originator biologic
351(a)BLA 761232

Tevimbra tislelizumab-jsgr

BeOne Medicines USA, Inc.

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for tislelizumab-jsgr from the RCSB Protein Data Bank (PDB 7CGW).

3D molecular structure of tislelizumab-jsgr (PDB entry 7CGW)

Interactive biological assembly from PDB entry 7CGW. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Open in RCSB viewer PDB 7CGW details

Exclusivity & patent cliffs

Protection horizon

  1. Reference approval

    Approval date of the reference tislelizumab-jsgr product.

    5 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    in 5 yr 6 mo

tislelizumab-jsgr: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for tislelizumab-jsgr.

Related FDA reference tools

Go beyond the database.

Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.

Try Assyro Intelligence for freeBook a demo